L-Glutamine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Using the Skill tool wasn’t needed here — this is a direct drug-repurposing report generation task matching the user’s explicit formatting instructions, so I’ll follow those directly.
L-Glutamine: From Nutritional Supplementation to Drug-Induced Osteoporosis
One-Sentence Summary
L-Glutamine is a non-essential amino acid conventionally used as a nutritional and immune-supportive agent; a specific original approved indication is not documented in this evidence pack. The TxGNN model predicts potential effectiveness for Drug-Induced Osteoporosis with a score of 99.98%, but this is currently supported by zero clinical trials and zero publications — the pipeline’s own mechanistic review flags this as a probable false positive rather than a genuine biological signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack (original_indications and original_moa are both unavailable) |
| Predicted New Indication | Drug-Induced Osteoporosis |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 (model prediction only, no supporting trials or literature) |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for L-Glutamine in this evidence pack. Based on general pharmacological knowledge, L-glutamine’s known actions relate to intestinal mucosal repair, immune modulation, and serving as a precursor for glutathione synthesis — none of which have an established link to osteoclast activity or bone remodelling pathways.
The evidence pack’s own repurposing rationale is explicit on this point: “No known mechanism: L-Glutamine acts mainly on mucosal repair, immune modulation and glutathione precursor synthesis, with no known connection to bone metabolism or osteoclast regulation pathways. The high TxGNN score may reflect knowledge-graph embedding similarity rather than a genuine biological mechanism.”
This is an important caveat: a high prediction score alone (99.98%) does not indicate biological plausibility. It most likely reflects structural similarity within the knowledge graph embedding space rather than a testable pharmacological hypothesis, and should not be treated as supportive evidence on its own.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
No UK marketing authorisations are recorded for L-Glutamine in this evidence pack (total_licenses = 0). Market status is recorded as Not marketed. No product-level data (formulation, licence numbers, approved indication text) is currently available for review.
Safety Considerations
No safety data (key warnings, contraindications, drug interactions) is currently available for L-Glutamine in this evidence pack. Notably, this is flagged in the underlying data as a Blocking gap (DG001 — MHRA/SmPC-equivalent warnings and contraindications), meaning even a preliminary safety screen (S1) cannot be completed until this is resolved.
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (drug-induced osteoporosis) has no supporting clinical trials or literature (L5) and the pipeline’s own mechanistic analysis identifies it as a likely embedding-similarity artefact rather than a biologically grounded hypothesis. Combined with a blocking gap in safety data, there is currently no basis to progress this candidate.
To proceed, the following is needed:
- Resolve DG001 (Blocking): obtain MHRA/SmPC-equivalent warnings and contraindications for L-Glutamine
- Resolve DG002: obtain a confirmed mechanism of action (e.g. via DrugBank API)
- Obtain baseline data on L-Glutamine’s original/current approved indication(s), which is currently missing entirely from this evidence pack
Separate note for consideration: among the ten candidates in this evidence pack, rank 3 (dermatitis) has a materially stronger evidence base than the top-ranked candidate — three RCTs (PMID 30753262, 28588793, 30587616) and a Phase NA completed trial (NCT03015077, n=59), reaching evidence level L2 with a “Research Question” recommendation. However, the evidence there is concentrated specifically in radiotherapy/chemotherapy-induced oral mucositis and dermatitis, not dermatitis broadly, and would need to be evaluated as its own narrower candidate rather than under the general “dermatitis” label.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.